Onbrez Breezhaler (Indacaterol)

Indacaterol, the active ingredient in Onbrez Breezhaler, is a long‑acting beta2‑adrenergic agonist presented as a dry‑powder inhalation formulation for inhalation use. It provides bronchodilation for maintenance therapy in adults with chronic obstructive pulmonary disease (COPD). GNH USA supplies Onbrez Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Onbrez Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Indacaterol is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow in chronic obstructive pulmonary disease.

- COPD maintenance therapy: improves lung function and reduces symptom burden. - Exercise intolerance in COPD: enhances exercise capacity and reduces dyspnoea. - Preventive bronchodilation: provides 24‑hour bronchodilation to reduce the need for rescue medication.

Adverse reactions reported with indacaterol inhalation are generally mild to moderate in severity.

Common Side Effects: - Cough - Throat irritation - Nasal congestion - Headache - Upper respiratory tract infection - Dry mouth

Serious or Rare Side Effects: - Paradoxical bronchospasm - Cardiovascular events such as tachycardia or palpitations - Severe allergic reactions (anaphylaxis) - Hypersensitivity skin rash - Pneumonia - Acute respiratory failure

When prescribing Onbrez Breezhaler, clinicians should consider several safety aspects.

- Assess risk of cardiovascular disease : review patient’s history and monitor heart rate and blood pressure. - Monitor for paradox bronchospasm : advise patients to stop treatment if worsening breath lessness occurs. - Review concomitant beta‑beta agonist use : avoid excessive β‑agonist exposure. - Caution in patients with severe renal impairment : dose adjustment is not required but monitor closely. - Educate on proper inhaler technique : incorrect use can reduce efficacy. - Store at ambient temperature: keep in original pack and protect from moisture.

Indacaterol may interact with other medicines that affect the cardiovascular or respiratory systems.

Major Interactions (Avoid): - Non‑selective β‑blockers : increased risk of reduced bronchodilation. - Monoamine oxidase inhibitors (MAOIs) : potential for heightened cardiovascular effects.

Moderate Interactions (Monitor Closely): - Other long‑acting β2‑agonists : additive bronchodilator effect may increase side‑effect risk. - Diuretics : may potentiate tachycardia. - Theophylline : monitor for increased theophylline levels. - Anticholinergic bronchodilators : watch for cumulative airway effects.